IL-12 CARvIII

IL-12 CARvIII is an "armored" chimeric antigen receptor (CAR) T-cell therapy developed by researchers at Duke University for the treatment of glioblastoma (GBM). The therapy consists of T cells engineered to express a CAR specific for the epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific deletion mutation frequently found in GBM. To enhance efficacy against heterogeneous tumors and overcome the immunosuppressive tumor microenvironment, these cells are further modified to constitutively secrete Interleukin-12 (IL-12), a pro-inflammatory cytokine that promotes T-cell survival, Th1 polarization, and the recruitment of endogenous immune cells. Preclinical data indicates that IL-12 CARvIII can achieve curative results in homogeneous tumor models and significantly extend survival in heterogeneous models by stimulating a robust endogenous CD8+ T-cell response.

Other names

IL-12 armored EGFRvIII-specific CAR T cellsIL12 armored EGFRvIII-specific CAR T cellsIL 12 armored EGFRvIII-specific CAR T cellsIL-12 armored CAR T cell therapyIL12 armored CAR T cell therapyIL 12 armored CAR T cell therapy